Background and Aims: The increasing prevalence of adolescent obesity affects adult health. We investigated the association of adolescent overweight with colorectal cancer incidence in a large cohort of males.Methods: Body mass index (BMI) was measured in 1.1 million Jewish Israeli males who underwent a general health examination at ages 16 to 19 between 1967 and 2005. Overweight was defined as BMI ! 85th percentile of the standard U.S. distribution in adolescence. Colorectal cancer was identified by linkage with the Israel National Cancer Registry up to 2006. The mean follow-up period was 17.6 AE 10.9 years, reflecting 19.5 million person-years. Cox proportional hazards modeling was used.Results: The prevalence of adolescent overweight increased from 9.9% to 16.8% in the first 10 and last 10 annual examination cohorts. Colon (n ¼ 445) and rectal cancer (n ¼ 193) cases were detected. Overweight predicted an increased risk of colon cancer [HR ¼ 1.53; 95% confidence interval (CI), 1.17-2.02, P ¼ 0.002] but not of rectal cancer (HR ¼ 1.09; 95% CI, 0.38-1.73, P ¼ 0.72). The risk was greatest for nonmucinous adenocarcinoma of the colon (HR ¼ 1.68, 95% CI, 1.26-2.23, P ¼ 0.001). The association of BMI ! 85th percentile with colon cancer was even more pronounced in analyses that were restricted to men followed until at least 40 years of age [N ¼ 367,478; HR ¼ 1.75 (95% CI, 1.33-2.3, P < 0.001)].Conclusions: Adolescent overweight is substantially associated with colon cancer incidence in young to middle-aged adults.Impact: These long-term sequelae add to the urgency to seriously address increasing childhood and adolescent obesity with its attendant increasing population impact. Cancer Epidemiol Biomarkers Prev; 20(12); 2524-31. Ó2011 AACR.

Objective/Hypothesis Anticoagulant and antiplatelet medications (ACAP) are known to be associated with an increased risk for epistaxis. There are conflicting results regarding the impact of Novel Oral Anticoagulants (NOAC) on epistaxis and its severity. Study Design Retrospective chart review of patients who were admitted to the ED in our tertiary level hospital with a diagnosis of epistaxis during the years 2012 to 2018. Methods Retrospective analysis of patients presenting to tertiary level emergency otolaryngological care during the years 2012 to 2018. The impact of various ACAP medications on epistaxis severity, hospital admission, and recurrence was analyzed. Results A total of 470 patients were identified. Two hundred and twenty‐nine patients (49%), were not on any anticoagulant/antiplatelet (ACAP) medications (controls) and 241 patients (51%) were taking at least one ACAP medication (ACAP group). Patients in the ACAP group were at a higher risk for severe epistaxis (OR = 1.8, P < .05) and were more likely to be hospitalized (OR = 2.17, P < .05). Surprisingly, the risk for recurrence was similar in the ACAP and control groups (15%, P > .05). Compared to controls, Warfarin and Enoxaparin increased the overall risk for severe epistaxis (OR = 4.4, P < .05) and for hospital admission (OR = 2.1, P < .05). Specifically, an increased risk for posterior tamponade (OR = 19, P < .001), significant blood loss (OR = 4.4, P = .032), and blood transfusion (OR = 4.7, P = .007) were identified as well. Interestingly, NOACs were not associated with increased risk for severe epistaxis, hospital admission, tamponade, and significant blood loss or blood transfusion compared to controls. Conclusions Compared to older generation anticoagulants and antiplatelet medications, NOACs demonstrated an improved safety profile, in terms of epistaxis severity, need for hospital admission and outcomes. These results may suggest a more conservative approach and less hospitalization when treating epistaxis in patients receiving NOACs. Level of Evidence 4 Laryngoscope, 131:1946–1951, 2021